As of 2026-03-06, the EV/EBITDA ratio of Turning Point Therapeutics Inc (TPTX) is -10.23. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TPTX's latest enterprise value is 3,484.99 mil USD. TPTX's TTM EBITDA according to its financial statements is -340.81 mil USD. Dividing these 2 quantities gives us the above TPTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.0x - 25.3x | 12.3x |
| Forward P/E multiples | 15.3x - 25.7x | 17.0x |
| Fair Price | (99.28) - (167.77) | (94.86) |
| Upside | -230.6% - -320.7% | -224.8% |
| Date | EV/EBITDA |